Additional Information

Description

Leqembi (lecanemab-irmb) is a monoclonal antibody directed against amyloid beta plaques, indicated for the treatment of Alzheimer’s disease. It is intended for patients in the mild cognitive impairment or mild dementia stages. The drug received accelerated approval based on its ability to reduce amyloid beta accumulation in the brain, a hallmark of Alzheimer’s pathology.

Leqembi is administered via intravenous infusion and requires careful patient selection and monitoring. Baseline assessments, including imaging for amyloid presence, are recommended before initiation. The dosing regimen involves an initial loading dose followed by maintenance infusions at scheduled intervals. Patients should be monitored for potential adverse effects, including amyloid-related imaging abnormalities (ARIA).

Common side effects associated with Leqembi include infusion-related reactions, headache, and ARIA, which may be asymptomatic or present with symptoms such as confusion, dizziness, or visual disturbances. Clinical monitoring, including periodic MRI scans, is advised to detect ARIA-related complications.